CTSH enters the post-earnings week under broad analyst pressure, with nearly every major firm trimming its price target while keeping ratings in place — a pattern that signals diminished confidence rather than outright capitulation.
The catalyst was April 29 earnings. The stock fell 4% on the day, as management guidance disappointed on visibility into the second half of the year. What followed was a coordinated wave of target cuts. Morgan Stanley lowered to $63 from $70. JPMorgan, maintaining its Overweight, cut to $74 from $92. Wells Fargo trimmed to $83 from $98 while staying positive. Mizuho, as recently as this morning, dropped its target to $68 from $87. Across the board, ratings held — but the targets moved sharply lower, with most now sitting in the $58–$88 range. The mean consensus target has settled near $74, against a stock that closed at $51.87 on Tuesday. That gap implies substantial upside on paper, but the direction of travel is downward, not upward.
The Street is split along a familiar axis. Bulls, including Guggenheim and Susquehanna, point to large deal signings, AI-led automation uptake, and margin discipline as reasons to stay constructive. Bears counter that discretionary demand is softening, annual contract value is declining, and second-half visibility remains thin. Management's own caution on the CY26 outlook is the core of the bear case — it's not that the business is broken, but that guidance is too opaque to price with confidence. The stock has now lost 17% over the past month, and the EV/EBITDA multiple, at roughly 5.7x, reflects a market demanding a discount for that uncertainty.
Short sellers have been active throughout the selloff, and the positioning data confirms it. Short interest has climbed to 8.3% of the free float — up from around 6.5% at the start of April, a rise of nearly 27% over six weeks. That pace of accumulation is notable. It accelerated sharply around the earnings date, with SI jumping from 7.6% in late April to above 8.1% in the days that followed. Borrow remains easy and cheap: cost to borrow is running at just 0.41%, and availability is wide, meaning there is no structural squeeze pressure in the lending market. Shorts are not fighting a tight borrow; they are adding freely into price weakness. Borrow availability is loose compared to levels that would typically signal stress — the 52-week high on utilization is only 7.1%, and the current reading is close to that peak. That tells you the lending pool is well-supplied, even as demand for borrows grows.
Options positioning has shifted meaningfully toward calls. The put/call ratio has dropped to 0.70, well below its 20-day average of 0.80 and near the 52-week low of 0.66. A standard-deviation pullback below average PCR suggests some investors are reaching for upside exposure — possibly speculating on a bounce off multi-month lows or hedging short positions with calls. The signal is worth noting precisely because it runs counter to the short-interest build: shorts are adding while some options participants are buying calls. The two signals don't cancel out, but they describe a market that is genuinely divided on direction.
Institutional ownership is stable and concentrated. Vanguard holds 12.7% of shares, BlackRock 9.4%, and Pzena — a value-oriented manager — increased its stake by 2.6 million shares in the most recent quarter, a meaningful addition at current levels. That Pzena is building rather than trimming suggests at least one value-focused shop sees the valuation compression as opportunity. The EV/EBIT factor score ranks in the 96th percentile of the universe, meaning the stock is trading cheap relative to its earnings power on that measure. The next earnings date is June 2. That print will be less about whether Cognizant can grow and more about whether management can deliver clarity on second-half demand — and whether the gap between the $74 consensus target and the $51.87 stock price starts to close or widen further.
See the live data behind this article on ORTEX.
Open CTSH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
